Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Three investment banks have initiated coverage of GenMark Diagnostics with favorable ratings.

Piper Jaffray issued an "overweight" rating and an $8 price target on GenMark's stock, saying its current valuation does not reflect the potential of the firm's technology or assay pipeline.

William Blair also initiated coverage with an "outperform" rating, and ThinkEquity initiated coverage with a "buy" rating.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19
Sponsored by
Roche

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).